NASDAQ:ACLX

Arcellx Stock Insider Trading

Healthcare > Biotechnology

Buy ACLX

*Your capital is at risk

$115.07

+0 (+0%)

At Close: Jun 03, 2026

Arcellx Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -63.73. In total, the insiders bought 1.66M and sold 6.21M ACLX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-63.73
● Buy	1.66M shares
● Sell	6.21M shares
32% Buy Activity Weak Negative Correlation
Sell Signal Medium Confidence Apr 28, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -63.73. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Apr 28, 2026 Sell	Restricted Stock Unit D-Return	Elghandour Rami See Remarks	Officer	208 333 Value: $0
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Elghandour Rami See Remarks	Officer	810 102 Value: $12.2M
Apr 28, 2026 Buy	Performance-based Restricted Stock Unit A-Award	Elghandour Rami See Remarks	Officer	147 745 Value: $17.0M
Apr 28, 2026 Buy	Performance-based Restricted Stock Unit A-Award	Elghandour Rami See Remarks	Officer	284 388 Value: $32.7M
Apr 28, 2026 Sell	Common Stock U-Tender	Heery Christopher Chief Medical Officer	Officer	23 749 Value: $2.73M
Apr 28, 2026 Sell	Restricted Stock Unit D-Return	Heery Christopher Chief Medical Officer	Officer	67 708 Value: $0
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Heery Christopher Chief Medical Officer	Officer	76 242 Value: $2.37M
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Heery Christopher Chief Medical Officer	Officer	43 604 Value: $273.8K
Apr 28, 2026 Buy	Performance-based Restricted Stock Unit A-Award	Heery Christopher Chief Medical Officer	Officer	45 138 Value: $5.19M
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Gilson Michelle Chief Financial Officer	C-Suite Officer	40 205 Value: $348.2K
Apr 28, 2026 Sell	Restricted Stock Unit D-Return	Gilson Michelle Chief Financial Officer	C-Suite Officer	88 542 Value: $0
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Gilson Michelle Chief Financial Officer	C-Suite Officer	94 596 Value: $5.31M
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Galligan Andrew H Director	Director	1 784 Value: $113.6K
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Galligan Andrew H Director	Director	16 829 Value: $1.18M
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Lubner David Charles Director	Director	9 174 Value: $584.2K
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Myers Kristin Director	Director	1 784 Value: $113.6K
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Myers Kristin Director	Director	16 829 Value: $1.18M
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Patel Kavita Director	Director	9 174 Value: $584.2K
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Patel Kavita Director	Director	8 011 Value: $411.0K
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Patel Kavita Director	Director	11 459 Value: $434.8K
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Patel Kavita Director	Director	20 513 Value: $307.7K
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Patel Kavita Director	Director	27 077 Value: $180.3K
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Behbahani Ali Director	Director	9 174 Value: $584.2K
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Behbahani Ali Director	Director	8 011 Value: $411.0K
Apr 28, 2026 Sell	Stock Option (right to buy) D-Return	Behbahani Ali Director	Director	11 459 Value: $434.8K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ARCELLX, INC.

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent Sp...

Read Full Profile Here